Botulinum toxin for conditions of the female pelvis

Dominique El-Khawand, Salim Wehbe, Kristene Whitmore

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction and hypothesis Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for thoseconditions. Methods A literature review of the most relevant reports published between 1985 and 2012. Results Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include: idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain. Conclusions Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.

Original languageEnglish (US)
Pages (from-to)1073-1081
Number of pages9
JournalInternational Urogynecology Journal and Pelvic Floor Dysfunction
Volume24
Issue number7
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Botulinum Toxins
Pelvis
Urinary Incontinence
Fissure in Ano
Off-Label Use
Interstitial Cystitis
Pain
Pelvic Floor
United States Food and Drug Administration
Ataxia
Urinary Bladder
Safety
Therapeutics
Research

Keywords

  • Anal fissure
  • Anismus
  • Botulinum toxin
  • High tone pelvic floor dysfunction
  • Interstitial cystitis
  • Neurogenic detrusor overactivity

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynecology

Cite this

Botulinum toxin for conditions of the female pelvis. / El-Khawand, Dominique; Wehbe, Salim; Whitmore, Kristene.

In: International Urogynecology Journal and Pelvic Floor Dysfunction, Vol. 24, No. 7, 07.2013, p. 1073-1081.

Research output: Contribution to journalArticle

El-Khawand, Dominique ; Wehbe, Salim ; Whitmore, Kristene. / Botulinum toxin for conditions of the female pelvis. In: International Urogynecology Journal and Pelvic Floor Dysfunction. 2013 ; Vol. 24, No. 7. pp. 1073-1081.
@article{d3671209a52a48e4a5e39dc9b6d4ee23,
title = "Botulinum toxin for conditions of the female pelvis",
abstract = "Introduction and hypothesis Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for thoseconditions. Methods A literature review of the most relevant reports published between 1985 and 2012. Results Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include: idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain. Conclusions Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.",
keywords = "Anal fissure, Anismus, Botulinum toxin, High tone pelvic floor dysfunction, Interstitial cystitis, Neurogenic detrusor overactivity",
author = "Dominique El-Khawand and Salim Wehbe and Kristene Whitmore",
year = "2013",
month = "7",
doi = "10.1007/s00192-012-2035-1",
language = "English (US)",
volume = "24",
pages = "1073--1081",
journal = "International Urogynecology Journal and Pelvic Floor Dysfunction",
issn = "0937-3462",
publisher = "Springer London",
number = "7",

}

TY - JOUR

T1 - Botulinum toxin for conditions of the female pelvis

AU - El-Khawand, Dominique

AU - Wehbe, Salim

AU - Whitmore, Kristene

PY - 2013/7

Y1 - 2013/7

N2 - Introduction and hypothesis Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for thoseconditions. Methods A literature review of the most relevant reports published between 1985 and 2012. Results Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include: idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain. Conclusions Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.

AB - Introduction and hypothesis Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for thoseconditions. Methods A literature review of the most relevant reports published between 1985 and 2012. Results Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include: idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain. Conclusions Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.

KW - Anal fissure

KW - Anismus

KW - Botulinum toxin

KW - High tone pelvic floor dysfunction

KW - Interstitial cystitis

KW - Neurogenic detrusor overactivity

UR - http://www.scopus.com/inward/record.url?scp=84886867364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886867364&partnerID=8YFLogxK

U2 - 10.1007/s00192-012-2035-1

DO - 10.1007/s00192-012-2035-1

M3 - Article

C2 - 23344218

AN - SCOPUS:84886867364

VL - 24

SP - 1073

EP - 1081

JO - International Urogynecology Journal and Pelvic Floor Dysfunction

JF - International Urogynecology Journal and Pelvic Floor Dysfunction

SN - 0937-3462

IS - 7

ER -